share_log

JMP Securities Reiterates Market Outperform on CRISPR Therapeutics, Maintains $86 Price Target

JMP Securities Reiterates Market Outperform on CRISPR Therapeutics, Maintains $86 Price Target

JMP证券重申对CRISPR Therapeutics的市场优于大盘评级,维持86美元的目标价
Benzinga ·  2024/12/20 21:52

JMP Securities analyst Silvan Tuerkcan reiterates CRISPR Therapeutics (NASDAQ:CRSP) with a Market Outperform and maintains $86 price target.

JMP证券分析师Silvan Tuerkcan重申对CRISPR Therapeutics(纳斯达克:CRSP)的市场优于大盘评级,维持86美元的目标价。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发